Aurinia Pharmaceuticals I... (AUPH)
7.83
-0.04 (-0.51%)
At close: Feb 20, 2025, 3:59 PM
7.83
0.00%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 7.79 |
| Market Cap | 1.12B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.15 |
| PE Ratio (ttm) | -52.2 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.98 |
| Volume | 1,096,938 |
| Avg. Volume (20D) | 1,330,771 |
| Open | 7.83 |
| Previous Close | 7.87 |
| Day's Range | 7.50 - 7.93 |
| 52-Week Range | 4.71 - 10.67 |
| Beta | undefined |
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada....
Industry Biotechnology
Sector Healthcare
IPO Date Sep 3, 2014
Employees 300
Stock Exchange NASDAQ
Ticker Symbol AUPH
Website https://www.auriniapharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 46.87% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Aurinia Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+10.9%
Aurinia Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
5 months ago
+0.77%
Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.
